The hearing — known as “Biosafety and Risky Research: Examining if Science is Outpacing Policy and Safety” — was called to also ensure that pathogen research in the U.S. is conducted as safely as possible.
The April 27 hearing will focus on follow-up information from a February meeting where witnesses detailed “obstacles to determining the root cause of infectious disease outbreaks and biological incidents,” according to the news release.
“Our Committee’s ongoing work has ignited heightened concerns about how we conduct and fund risky research and whether current biosafety measures are still sufficient to mitigate risks,” Reps. Morgan Griffith and Cathy McMorris Rodgers, who chair committees that oversee the initiative, said in a joint statement. “This hearing will provide members and the public an opportunity to better understand specific risks involved with gain-of-function research on potential pandemic pathogens, current biosafety practices at high-containment laboratories, and will help better inform upcoming policymaking decisions.”
Becker’s will continue to follow this coverage and report on new information from the April 27 hearing once it is available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
